Finn
ADPT Diagnostics · Cancer diagnostics · MRD testing · Biotech tools · Thesis updated November 15, 2026

Total company profitability achieved as clonoSEQ clinical adoption accelerates.

01 Running thesis

A sharper focus yields total company profitability

Adaptive reached a major milestone in the third quarter of 2026 by achieving total company profitability ahead of expectations. The main story remains clonoSEQ, a test for minimal residual disease that detects tiny amounts of cancer left after treatment. MRD clinical volume grew 46% year-over-year, and the external environment is shifting forcefully in the company favor. Updated NCCN guidelines and a new International Myeloma Working Group definition of cure now effectively mandate the highly sensitive serial testing that clonoSEQ provides.

The bull case is exceptionally strong following Q3 2026. The core MRD business is growing rapidly and has validated its unit economics by driving the entire company to profitability. Adaptive has submitted a technical assessment to MolDX for a new maintenance bundle in multiple myeloma. If approved, this stands as a primary catalyst for average selling price expansion and recurring revenue.

The bear case centers on heavy product concentration and the risks of a complex transition. MRD testing accounted for 86% of revenue in the recent quarter. The planned separation of the Immune Medicine segment introduces near-term execution risk, uncertainty around the final structure, and questions about how to handle $345 million in convertible debt. There is also near-term pressure on realized average selling prices until the new maintenance bundle is secured.

Investors currently value the company largely for its MRD growth and newly proven profitability. A pending corporate restructuring and a minor reimbursement headline risk regarding erroneous preliminary data submitted to CMS require close monitoring.

Nov 2026▲Q3 2026 marked a major milestone as the company achieved total profitability ahead of expectations. MRD clinical volume grew 46% year-over-year.
Aug 2026▲Q2 2026 results revealed plans to separate the MRD and Immune Medicine businesses by year-end. MRD revenue continued to grow fast.
May 2026▲Q1 2026 confirmed the MRD thesis. MRD revenue grew 53%, clonoSEQ volume grew 41%, and management raised 2026 MRD revenue guidance.
May 2026→The Q1 2026 filing showed Immune Medicine revenue down 57% after the Genentech wind-down. This did not change the main thesis, but it made the concentration risk clearer.
Feb 2026▲The FY2025 filing showed MRD revenue of $212.3 million, up 46%, with clonoSEQ test volume up 39%. The new Medicare price also increased by 17% from the prior rate.
Nov 2025▼The Genentech collaboration was terminated, removing a major Immune Medicine partner. A one-time revenue benefit helped GAAP profit in the quarter, but it was not a normal run-rate.
Aug 2025▲Q2 2025 showed MRD revenue growth of 42% and the segment reached positive Adjusted EBITDA for the first time. Company-wide cash burn also improved.
May 2025▲Q1 2025 showed MRD revenue growth of 34% and clonoSEQ volume growth of 36%. The net loss narrowed versus the prior year.
02 Business model

Restructuring toward pure diagnostics and maintenance testing

Adaptive historically made money in two segments: MRD and Immune Medicine. MRD is the core business. It sells clonoSEQ testing to doctors who monitor blood cancers and to biopharma companies that use the test in drug studies. This diagnostic side has consistent growth, clear pricing, and recently pushed the entire company into profitability.

The Immune Medicine segment previously sold immunosequencing research services, data licensing, and discovery partnerships. However, in July 2026, the company decided to wind down its research-use-only pharma services to focus exclusively on its target discovery platform and data models.

The biggest structural change is the plan to separate these two segments entirely by the end of 2026. The goal is to let the profitable MRD business operate without funding early-stage Immune Medicine research.

The company relies heavily on clinical guidelines to drive test volume. Recent updates recommending testing at a sensitivity level uniquely provided by clonoSEQ give the company a powerful mandate to sell serial testing bundles to clinics.

03 Product portfolio

What Adaptive sells

Growth engine

clonoSEQ for clinical care

clonoSEQ is the main product. It helps doctors detect and monitor tiny traces of cancer in multiple myeloma and other lymphoid cancers.

Growth engine

clonoSEQ for biopharma trials

Drug companies use clonoSEQ testing in studies to measure how well cancer drugs clear disease.

Option

TCR discovery and antigen maps

Adaptive uses immune receptor data to connect T cells with the targets they recognize. This includes data licensing agreements with partners like Pfizer.

Steady

Adaptive Immunosequencing

This research-use service reads immune receptor data. The company is winding down this offering in the second half of 2026.

04 Business segments

MRD takes over the mix

MRD86%growing fast
Immune Medicine14%declining

Based on internal management disclosures in Q3 2026, the Minimal Residual Disease segment accounted for 86% of total revenue. This makes clonoSEQ the primary value driver ahead of the planned separation.

05 Risk factors

What could go wrong

Execution of the corporate split

High impact · Medium odds

The planned separation of the MRD and Immune Medicine segments by year-end 2026 is complex. It could incur high costs, distract management, or fail to find a viable path for the Immune Medicine assets.

We watchUpdates on the separation structure and associated restructuring costs.

clonoSEQ concentration

High impact · High odds

MRD made up 86% of recent quarterly revenue. That means one product line drives almost the whole company. Any slowdown in clonoSEQ volumes would severely damage the core business valuation.

We watchQuarterly clonoSEQ test volume growth and clinical adoption rates.

Reimbursement and pricing pressure

Medium impact · Medium odds

Erroneous PLA data submitted to CMS created near-term headline risk for preliminary rates. As testing frequency increases, there is also pressure on realized average selling prices until a new maintenance bundle is secured.

We watchCMS final rate announcements and the approval of the MolDX maintenance testing bundle.

New debt burden

Medium impact · Medium odds

The company issued $345 million in convertible notes in June 2026. This increases leverage before the separation is complete and could limit future cash flow flexibility.

We watchInterest expenses and how the debt is apportioned between the separated entities.
06 Quick answers

In one breath

What does Adaptive Biotechnologies do?

Adaptive reads immune-system data and sells tests based on that data. Its main product is clonoSEQ, a cancer monitoring test for minimal residual disease.

Why is clonoSEQ important?

clonoSEQ helps detect very small amounts of cancer left after treatment. The business built around clonoSEQ drives the vast majority of company revenue.

Is the company splitting up?

Yes. In June 2026, Adaptive announced a plan to separate its MRD and Immune Medicine businesses by the end of 2026.

What happened to the immunosequencing service?

Adaptive announced in July 2026 that it is winding down its research-use-only immunosequencing offering to focus purely on target discovery and data models.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Adaptive Biotechnologies Q3 2026 earnings call transcript
  2. Adaptive Biotechnologies Q2 2026 Form 10-Q
  3. Adaptive Biotechnologies FY2025 Form 10-K
08 Explore the industry

Comparable Biotechnology companies

Companies near Adaptive Biotechnologies Corporation in Finn's Biotechnology industry ranking.

Get started with Finn today